Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Faricimab in Diabetic Macular Edema (Japan LTE of YOSEMITE/RHINE)
jRCT2031200318Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of faricimab in diabetic macular edema (DME), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Incidence and severity of ocular adverse events and Incidence and severity of systemic (non-ocular) adverse events. Started Jan 2021; status: completed.
02
Drugs
faricimab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCT2031200318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200318.